SolasCure
Manufacturing · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Wellington House East Rd, Cambridge, Cam...Phone Number
+44 1223827959Website
www.solascure.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About SolasCure
Founded in 2017, based out of United Kingdom, SolasCure Limited aims to support healthcare professionals with wound care products that significantly improve the health and wellbeing of patients with chronic wounds. SolasCures first product, Aurase is a hydrogel containing a safe, active, highly-specific enzyme, isolated and cloned from medical maggots. The medical use of Aurase should lead to faster wound cleaning promoting better patient outcomes and reduced healthcare costs.Explore more
SolasCure Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is SolasCure your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if SolasCure had a recent Job posting/layoffs
Check if SolasCure has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once SolasCure has new funding data
Congratulate Masked Content for being promoted to Masked Content at SolasCure
Check out if SolasCure is spiking on competitors!
Earning: See what the market has to say on SolasCure recently announced quarterly report
Product Launch: Get notified when SolasCure launches new products
SolasCure, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined SolasCure as Masked Content
Find 2 more new buyers
Compare Similar Companies to SolasCure
Compare insights from companies similar to SolasCure, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
SolasCure is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
SolasCure is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about SolasCure.
SolasCure financials insights
Gather financial insights about SolasCure, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$20.8M
Unspecified
$1.6M
2023
Series B
$13.4M
SolasCure Tech Stack
A closer look at the technologies used by SolasCure
See more technologies
Most Recent Scoops
Funding
Funding
Funding
Funding
SolasCure News & Media
SolasCure Enrols First Patient in a Next Phase II Clinical Trial to Advance Aurase Wound Gel
CAMBRIDGE, England--(BUSINESS WIRE)--SOLASCURE Ltd (SolasCure), a biotechnology company developing a novel treatment to transform chronic wound healing, today announced the initiation of a new Phase II clinical trial, CLEANVLU2. The enrolment of the trial’s first patient marks a new clinical milestone in the development of its investigational product, Aurase Wound Gel, for the treatment of chronic wounds. Aurase Wound Gel is a hydrogel releasing Tarumase, a recombinant enzyme originally clonedSolasCure and U.S. Army Institute of Surgical Research Collaborate for Combat Wound Care
CAMBRIDGE, England & SAN ANTONIO--(BUSINESS WIRE)--SOLASCURE Ltd (“SolasCure”), a biotechnology company developing a novel treatment to transform chronic wound care and the U.S. Army Institute of Surgical Research (“USAISR”), today announced a research collaboration to evaluate SolasCure’s investigational product, Aurase Wound Gel, as a means for managing combat wounds. Aurase Wound Gel is a hydrogel releasing tarumase, a recombinant enzyme derived from medical maggots, which is currently beingSolasCure Selected for Innovate UK Global Incubator Programme in Houston
CAMBRIDGE, England--(BUSINESS WIRE)--SOLASCURE Ltd (SolasCure), a biotechnology company developing a novel treatment to transform chronic wound care, today announced it has been selected for Innovate UK’s Global Incubator Programme in Houston, US. The programme, which is focused on commercialising innovative solutions for unmet healthcare needs, is delivered in partnership with the Texas Medical Centre (TMC), the largest medical complex globally. The programme will support the future entry of ASolasCure Publishes Phase IIa Clinical Trial Report in Leading Wound Care Journal
CAMBRIDGE, England--(BUSINESS WIRE)--SOLASCURE Ltd (SolasCure), a biotechnology company developing a novel treatment to transform chronic wound care, has today announced the publication of its CLEANVLU Phase IIa clinical trial report in the International Wound Journal, a leading wound care journal.1 SolasCure’s first investigational product, Aurase Wound Gel, is a hydrogel releasing tarumase (provisional INN), a recombinant enzyme derived from medical maggots, which aims to promote wound healin
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding SolasCure
Sign Up For FreeTo access detailed company insights
Founded in 2017, based out of United Kingdom, SolasCure Limited aims to support healthcare professionals with wound care products that significantly improve the health and wellbeing of patients with chronic wounds. SolasCures first product, Aurase is a hydrogel containing a safe, active, highly-specific enzyme, isolated and cloned from medical magg... Read More
